Optimized for Accuracy, Reproducibility and Sample Adaptability

Ion Semiconductor Sequencing Chemistry

Ion Semiconductor Sequencing Chemistry

Sequencing by Synthesis Sequencing Chemistry

Sequencing by Synthesis Sequencing Chemistry

NeoGenomics' Pharma Services provides numerous applications and platforms for next-gen sequencing. NeoGenomics is one of the early adopters of next-gen sequencing and has extensive experience with a variety of projects.

NeoGenomics sequencing platforms includes numerous models from Illumina; like the HiSeq, MiSeq and NextSeq. Additionally, we offer Life Technologies Ion Torrent sequencers for use on your project.

We offer rapid turnaround times, cost-effective pricing and project managers to collaborate with you at every step of the way. Our service offerings are flexible and scalable to meet your needs; whether your project is a few samples or a few thousand with clinical trial sites all over the world, we can help.


Some of the Popular Services We Offer:


Neoantigens

Tumor-specific antigens or neoantigens are non-native protein sequences specifically expressed by cancer cells. Neoantigens may be recognized by the host immune system as "foreign" and thereby offers a tumor-specific target. Within the field of immune-oncology, neoantigens have been used to develop personalized cancer vaccines by priming the host’s immune system to specifically recognize tumor cells for destruction.

Tumors with a high burden of neoantigens are more sensitive to immunotherapy, indicating that neoantigens may be a potential I-O biomarker. As immunogenic neoantigens can be challenging to identify directly, TMB may potentially be used as a surrogate to individually assess neoantigen load. At NeoGenomics, we offer a neoantigen discovery workflow by leveraging our comprehensive genomics offerings including WES, RNA Sequencing and bioinformatics data analysis.

  1. Whole exome sequencing of the tumor as well as matched normal from peripheral blood. Non-synonymous mutations, or those that translate into a non-native protein sequence are identified. Those that are present in normal tissue, are filtered out as they are not recognized to be foreign.
  2. Whole transcriptome sequencing of the tumor tissue. The non-synonymous tumor specific mutations that are transcribed at high levels are identified by RNA-Seq. They are most likely to be presented on the cell surface for immune system recognition.
  3. HLA typing – Four digit resolution obtained from whole exome and/or transcriptome data.
  4. Neoantigen peptide ranking. Binding to HLA molecules is predicted by 3 independent neural nets.